Proposal for Slightly Revised USP Chapter <711> Dissolution Published

Recommendation

4/5 October 2022

FDA Compliance in Analytical Laboratories - Live Online Training
How to implement cGMP requirements in the everyday practice of quality control laboratories

In November 2021, we reported that the Dosage Forms Expert Committee intends to revise General Chapter <711> Dissolution. Please read the related news article for more information.

The new version of the chapter was now published for comments in the current Pharmacopeial Forum, PF 48(2). The briefing note states that the "proposal is based on the version of the chapter to be official on May 1, 2022. The purpose of this revision is to include an option of using a new USP Reference Standard, USP Dissolution Performance Verification Standard-Prednisone RS, to qualify the Dissolution Apparatus 1 (basket) and Dissolution Apparatus 2 (paddle), in addition to USP Prednisone Tablets RS, which is already included in the official version of this chapter."

The proposal can be consulted after registration on the Pharmacopeial Forum website. Comments can be submitted until May 31, 2022. In the absence of significant adverse comments, it is proposed to implement the new revision via an Interim Revision Announcement with an official date of September 1, 2022.